Clinical trials: Histological Type of Neoplasm
Malignant Melanoma
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
- Trial name
- PXS-X02 (NCT00235482)
- Testing
- Coxsackievirus A21
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Viralytics
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Neuroblastoma
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them before surgery, may shrink the tumor so that it can be removed…
- Trial name
- NCT00025623
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 11 sites in Austria, Belgium and 9 more
- Sponsor
- European Infant Neuroblastoma Study Group - 1999
Stage IV Resectable Melanoma
Stage IV Surgery Versus Best Medical Therapy
This study will establish the role of surgical versus nonsurgical approaches in patients whose melanoma has spread to distant sites.
- Trial name
- STG4SURG (NCT01013623)
- Testing
- Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 12 people
- Sponsor
- Saint John's Cancer Institute
Glioblastoma
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly…
- Trial name
- NCT02997423
- Where
- 19 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Iowa
Lymphoma, Large B-Cell, Diffuse
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and…
- Trial name
- NCT06289959
- Testing
- cfDNA
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Merkel Cell Carcinoma
Merkel Positron Emission Tomography (PET) Protocol
A Phase II Study designed to evaluate the efficacy of Chemo-Radiotherapy in achieving loco-regional control in patients with Merkel Cell Carcinoma (MCC) of the skin.
- Trial name
- MP3 (NCT01013779)
- Testing
- Carboplatin, Etoposide, Radiotherapy
- Where
- 13 sites in Australia
- Volunteers
- 43 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel
There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis.
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00159003
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Deborah Rund
Lymphoma
Effect of Interactive Tailored Assessment on Patient-provider Communication
This interdisciplinary international research collaboration will test effects of Choice, a computer-assisted, interactive support system designed to help cancer patients communicate their symptoms and preferences, and clinicians…
- Trial name
- NCT00857103
- Testing
- CHOICE
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Mesothelioma; Lung
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
This study aims to find the maximum tolerated dose level for malignant pleural mesothelioma patients receiving background radiation + boost radiation, and surgery.
- Trial name
- SMARTER (NCT04028570)
- Testing
- Varying Doses of Background and Boost RT
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia, Measurable Residual Disease
Motixafortide for MRD Sensitization in AML
This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid leukemia (AML) who have completed induction treatment.
- Trial name
- NCT07392970
- Testing
- Motixafortide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00301769
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Fibroids
Post Market Evaluation of Acessa With TAG
The purpose of this study is to test both user preference and speed of targeting with the use of the Acessa System with Targeting Animation Guidance (TAG).
- Trial name
- TAG (NCT01842789)
- Testing
- Acessa Procedure
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Acessa Health, Inc.
Sarcoma
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00740597
- Testing
- gene expression analysis, polymerase chain reaction, western blotting
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Nasopharyngeal Carcinoma
Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients
The purpose of this study is to evaluate whether dietary nitrate supplementation could improve the salivary flow for nasopharyngeal carcinoma patients receiving concurrent chemo-radiation therapy.
- Trial name
- NCT02854410
- Testing
- Sodium nitrate, sodium chloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Capital Medical University
Multiple Myeloma
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment.
- Trial name
- NCT07624513
- Testing
- Isatuximab, Iberdomide, Bortezomib (B)
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Nutritional Assessment Intervention to Improve Cancer-Related Fatigue
Primary Objective: 1. To use the results from this pilot study to estimate the effect size of the nutritional intervention on fatigue and caloric intake. Secondary Objectives: 1.
- Conditions
- Leukemia, Lymphoma, Fatigue
- Trial name
- NCT00507260
- Testing
- Food Record, Nutritional Consults
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma, Kidney Cancer
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal
- Trial name
- NCT04260360
- Testing
- NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC
Leukemia, Lymphoma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00027560
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.